Abstract
Background Between 1999 and 2021, 505 culture-confirmed cases of M. bovis disease in humans (zoonotic tuberculosis, TB) were identified in England. We aimed to estimate the prevalence of M. bovis infection in persons exposed to TB-infected cattle in England and identify any risk factors associated with latent TB infection (LTBI) in this population.
Methods We co-developed a retrospective cohort study in southwest England, a bovine TB high risk area, with members of the UK farming community. A questionnaire captured participant characteristics, behaviours and farming practices. Linkage with historical herd testing data was used to categorise participants as low, medium or high risk for TB exposure. Interferon gamma release assay (IGRA) positivity with Quantiferon was used to determine LTBI status and linked to questionnaire data.
Results We recruited 90 participants at agricultural shows and a standalone event. Participants were farmers/farm workers (79/90) and veterinary professionals (11/90). Median age was 45.5 years (IQR: 19–77); 58% were male; 66% reported BCG vaccination. M. bovis exposure was via direct contact with infected cattle and consumption of raw milk. One participant in the high-risk group was IGRA positive, all other participants were IGRA negative. Estimated IGRA positivity rate was 1.1% (95% CI 0.058%–7.0%) in all participants and 4.0% (95%CI 0.21%–22%) in participants with high exposure levels.
Conclusions We found limited LTBI in individuals in contact with TB-infected cattle in England, despite high and prolonged exposure. We identified a high-risk group of farmers who should be prioritised for future engagement.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://zootb.blogs.bristol.ac.uk/study-protocol/
Funding Statement
The study and AT were funded by a Wellcome Trust Seed Award 217509/Z/19/Z. The NIHR HPRU in Behavioural Science and Evaluation at the University of Bristol supported PPIE. CM time was supported by the National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) and the National Institute for Health and Care Research Health Protection Research Unit in Behavioural Science and Evaluation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was granted ethical approval by the NHS Health Research Authority Research Ethics Committee (REC) on 4 October 2021 and the amendment to expand the eligibility criteria was approved on 22 July 2022 (REC reference 21/YH/0241).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data availability statement Anonymised questionnaire data for participants who consented for further research use are available to researchers upon request at https://data.bris.ac.uk/.
Funding statement The study and AT were funded by a Wellcome Trust Seed Award 217509/Z/19/Z. The NIHR HPRU in Behavioural Science and Evaluation at the University of Bristol supported PPIE. CM time was supported by the National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) and the National Institute for Health and Care Research Health Protection Research Unit in Behavioural Science and Evaluation.
Conflict of interest disclosure There are no conflicts of interest to disclose.
Ethics approval statement The study was granted ethical approval by the NHS Health Research Authority Research Ethics Committee (REC) on 4 October 2021 and the amendment to expand the eligibility criteria was approved on 22 July 2022 (REC reference 21/YH/0241).
Patient consent statement All participants provided written consent to take part.
(amyc.thomas{at}bristol.ac.uk)
(alice.halliday{at}bristol.ac.uk)
(pu18699{at}bristol.ac.uk)
(zooTB-study{at}bristol.ac.uk)
(hopewell-kellyn2{at}cardiff.ac.uk)
(carmel.mcgrath{at}uwe.ac.uk)
(lucy.wheeler{at}nbt.nhs.uk)
(Anna.Dacey{at}nbt.nhs.uk)
(Nigel.Noel{at}nbt.nhs.uk)
(andrea.turner{at}bristol.ac.uk)
(isabel.oliver{at}phe.gov.uk)
(jlnw2{at}cam.ac.uk)
(ed.moran{at}nbt.nhs.uk)
(pfvir{at}aol.com)
(anu.goenka{at}bristol.ac.uk)
Data Availability
Anonymised questionnaire data for participants who consented for further research use are available to researchers upon request at https://data.bris.ac.uk/.
